Technology Innovation at GW: A Success Story

Akos Vertes, GW Chemistry Professor

Success Stories

The Technology Commercialization Office (TCO) licenses George Washington University (GW) inventions to companies to develope into products for the market.  Income from inventions that become licensed and commercialized fund more research at GW. GW Inventors, students and faculty, learn about the patent process and about product development, improving their career opportunities.

A Top 10 Innovation on IN-PART

George Washington inventors Dr. Stephen Hsu and Dr. Fei Zhao created a new way to microencapsulate chemical additives for engine lubrication. This invention was one of the top 10 innovations that generated the most interest from the global R&D community on the IN-PART platform in Q3 of 2019. Technology Summary on IN-PART for the microencapsulation

 

La Jolla Pharmaceutical Company (Nasdaq: LJPC), develops innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases. La Jolla entered into an exclusive worldwide license agreement for GW intellectual property rights covering the use of angiotensin II for the therapeutic treatment of patients with hypotension and shock. A few months after the license was completed, La Jolla began a phase 3 clinical trial of LJPC-501, La Jolla’s proprietary formulation of angiotensin II, in catecholamine-resistant hypotension (CRH). In 2017, La Jolla announced positive results from the completed phase 3 trial, with highly significant efficacy for restoration of patients' blood pressure and a trend toward longer survival. On December 21, 2017 the U.S. Food and Drug Administration approved GiaprezaTM (angiotensin II) for increasing blood pressure in adults with septic or other distributive shock. La Jolla launched GiaprezaTM sales in the U.S. in 2018. La Jolla sublicensed GiaprezaTM rights to Paion AG for sales in Europe in 2021.

 

Phantom Space logo
 

Phantom Space Corporation licensed the Plasma Thruster technology developed in the laboratory of GW Professor Michael Keidar. Dr. Keidar's plasma thruster helps microsatellites access and maintain desired orbital positions efficiently. The company was founded by one of the original SpaceX founding members and its innovative solutions help to connect space startups with reliable and affordable space access. Phantom is leading space exploration with miniature satellites made from common materials that are significantly less expensive than their larger counterparts.  In addition, Phantom works to revolutionize the software behind these satellites by increasing their speed and access. The company uses two launch vehicles for their satellites: one launch vehicle (Daytona) launches 450kg into orbit; the second launch vehicle (Laguna) launches 1200kg into orbit.

 

Welltok logoText2Quit helps smokers who want to quit now with an interactive mobile-based smoking cessation tool developed by Dr. Lorien Abroms of the Milken Institute School of Public Health. Dr. Abroms developed the Text2Quit program under sponsorship from the National Cancer Institute. She also created Quit4Baby to help pregnant women quit smoking. The programs offer customized educational messages based on the user's own quit-date and personalized advice on quitting. Welltok inc., a Virgin Pulse company, through a series of mergers and acquisitions, licensed the intellectual property behind the Text2Quit program from the GW and delivers the Text2Quit program on a subscription basis through employers, health plans and public health departments.